Compare PAYS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYS | TOVX |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 7.3M |
| IPO Year | 1998 | 2006 |
| Metric | PAYS | TOVX |
|---|---|---|
| Price | $5.15 | $0.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.06 | N/A |
| AVG Volume (30 Days) | 277.5K | ★ 10.1M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $74,879,428.00 | N/A |
| Revenue This Year | $41.20 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | $39.56 | ★ N/A |
| Revenue Growth | ★ 32.61 | N/A |
| 52 Week Low | $1.80 | $0.17 |
| 52 Week High | $8.88 | $2.03 |
| Indicator | PAYS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 46.21 |
| Support Level | $5.11 | $0.18 |
| Resistance Level | $5.38 | $0.23 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 20.54 | 58.19 |
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.